Brief: Janux Therapeutics Announces FDA Clearance Of Investigational New Drug Application For Janx007
31/05/2022 13:06
May 31 (Reuters) - Janux Therapeutics Inc JANX.O :
* JANUX THERAPEUTICS ANNOUNCES FDA CLEARANCE OF
INVESTIGATIONAL
NEW DRUG APPLICATION FOR JANX007, A PSMA-TRACTR FOR METASTATIC
CASTRATION-RESISTANT PROSTATE CANCER
* JANUX THERAPEUTICS INC - PHASE 1 CLINICAL STUDY OF
PSMA-TRACTR
(JANX007) EXPECTED TO INITIATE IN 2H 2022
Source text for Eikon: ID:nBw31xC1Ja
Further company coverage: JANX.O